Department of Pulmonology, Hospital Universitari Mútua Terrassa, Terrassa, Spain; School of Medicine, University of Barcelona, Barcelona, Spain; Network of Centers for Biomedical Research in Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Spain.
Department of Pulmonology, Hospital Universitari Mútua Terrassa, Terrassa, Spain; School of Medicine, University of Barcelona, Barcelona, Spain.
Ann Thorac Surg. 2021 Apr;111(4):1190-1197. doi: 10.1016/j.athoracsur.2020.06.040. Epub 2020 Aug 24.
In patients with non-small cell lung cancer (NSCLC) and normal mediastinum, the central tumor location predicts occult nodal disease (both N1 and N2). We evaluated a novel definition of central location based on a geometrical measurement of the tumor location within the lung that could predict N2, N1, or both.
This retrospective study included patients with confirmed NSCLC, radiologically and metabolically staged T1 N0 M0, who underwent invasive mediastinal staging and/or lung resection. The central tumor location was measured considering 2 ratios. The inner margin ratio (IMR) and outer margin ratio (OMR) were both calculated as the distance from the inner margin of the lung to both margins of the tumor (inner [IMR], outer [OMR]) divided by the lung width. Optimal cutoffs for IMR and OMR were calculated. Tumors with values lower than the cutoffs were considered central. Prevalences of N1 and N2 upstaging were estimated and bivariate logistic regression analysis was performed to predict the odds of N1 and N2 upstaging using IMR and OMR cutoffs.
A total of 209 patients were included. The prevalence of N1 and N2 upstaging was 11% and 5.3%, respectively. Cutoffs of 0.5 for IMR and 0.64 for OMR were estimated. Both ratios predicted N1 upstaging (adjusted odds ratio [95% confidence interval]: 4.2 [1.5-12]; P < .007; area under the curve, 0.65) but did not predict N2 upstaging.
Central tumor location can be assessed by means of IMR and OMR and predicts N1 upstaging in patients with radiologically and metabolically T1 N0 M0 tumors. This is important for the selection of patients for therapies that require N0 tumors.
在非小细胞肺癌(NSCLC)且纵隔正常的患者中,中央肿瘤位置预测隐匿性淋巴结疾病(N1 和 N2 均有)。我们评估了一种基于肿瘤在肺内位置的几何测量的新的中央位置定义,这种定义可以预测 N2、N1 或两者。
本回顾性研究纳入了经影像学和代谢分期为 T1N0M0 的确诊 NSCLC 患者,他们接受了侵袭性纵隔分期和/或肺切除术。中央肿瘤位置通过考虑 2 个比值来测量。内缘比(IMR)和外缘比(OMR)均为肿瘤内缘到肿瘤两个边缘的距离(内缘 [IMR]、外缘 [OMR])除以肺宽。计算 IMR 和 OMR 的最佳截止值。低于截止值的肿瘤被认为是中央的。估计了 N1 和 N2 升级的患病率,并进行了二元逻辑回归分析,使用 IMR 和 OMR 截止值来预测 N1 和 N2 升级的几率。
共纳入 209 例患者。N1 和 N2 升级的患病率分别为 11%和 5.3%。估计 IMR 的截止值为 0.5,OMR 的截止值为 0.64。这两个比值均预测 N1 升级(调整后的优势比 [95%置信区间]:4.2 [1.5-12];P <.007;曲线下面积,0.65),但不预测 N2 升级。
可以通过 IMR 和 OMR 评估中央肿瘤位置,预测影像学和代谢 T1N0M0 肿瘤患者的 N1 升级。这对于选择需要 N0 肿瘤的治疗方法的患者很重要。